Search Results - "Klingman, Karin L"

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects by STONE, Nimalie D, DUNAWAY, Shelia B, PARK, Jeong-Gun, LALAMA, Christina, SNYDER, Sally, KALLUNGAL, Beatrice, KLINGMAN, Karin L, HENDRIX, Craig W, FLEXNER, Charles, TIERNEY, Camlin, CALANDRA, Gary B, BECKER, Stephen, CAO, Ying-Jun, WIGGINS, Ilene P, CONLEY, Jeanne, MACFARLAND, Ron T

“…ERRATUM ( vol. 51 , p. 3047 ) Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg…”
Get full text

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial by O'Connor, Jemma, MSc, Vjecha, Michael J, MD, Phillips, Andrew N, Prof, Angus, Brian, Prof, Cooper, David, Prof, Grinsztejn, Beatriz, MD, Lopardo, Gustavo, MD, Das, Satyajit, Prof, Wood, Robin, Prof, Wilkin, Aimee, MD, Klinker, Hartwig, MD, Kantipong, Pacharee, MD, Klingman, Karin L, MD, Jilich, David, MD, Herieka, Elbushra, MD, Denning, Eileen, MPH, Abubakar, Ibrahim, Prof, Gordin, Fred, Prof, Lundgren, Jens D, Prof

“…Summary Background The effects of antiretroviral therapy on risk of severe bacterial infections in people with high CD4 cell counts have not been well…”
Get full text

Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1–infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275) by Nixon, Daniel E., DO, PhD, Bosch, Ronald J., PhD, Chan, Ellen S., MSc, Funderburg, Nicholas T., PhD, Hodder, Sally, MD, Lake, Jordan E., MD, Lederman, Michael M., MD, Klingman, Karin L., MD, Aberg, Judith A., MD

“…Background Persistent immune activation and inflammation in virologically suppressed human immunodeficiency virus (HIV) infection are linked to excess…”
Get full text

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection by Lundgren, Jens D, Babiker, Abdel G, Gordin, Fred, Emery, Sean, Grund, Birgit, Sharma, Shweta, Avihingsanon, Anchalee, Cooper, David A, Fätkenheuer, Gerd, Llibre, Josep M, Molina, Jean-Michel, Munderi, Paula, Schechter, Mauro, Wood, Robin, Klingman, Karin L, Collins, Simon, Lane, H Clifford, Phillips, Andrew N, Neaton, James D

“…When to start antiretroviral therapy for HIV infection on the basis of the CD4+ count has been controversial. In a global randomized trial, treatment of…”
Get full text

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination by Fitch, Kathleen V, Kileel, Emma M, Looby, Sara E, Zanni, Markella V, Sanchez, Laura R, Fichtenbaum, Carl J, Overton, Edgar T, Malvestutto, Carlos, Aberg, Judith A, Klingman, Karin L, Alston-Smith, Beverly, Lavelle, Judith, Rancourt, Anne, Badal-Faesen, Sharlaa, Cardoso, Sandra Wagner, Avihingsanon, Anchalee, Patil, Sandesh, Sponseller, Craig A, Melbourne, Kathleen, Ribaudo, Heather J, Cooper-Arnold, Katharine, Desvigne-Nickens, Patrice, Hoffmann, Udo, Douglas, Pamela S, Grinspoon, Steven K

“…The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin…”
Get full text

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) by Grinspoon, Steven K., Fitch, Kathleen V., Overton, Edgar Turner, Fichtenbaum, Carl J., Zanni, Markella V., Aberg, Judith A., Malvestutto, Carlos, Lu, Michael T., Currier, Judith S., Sponseller, Craig A., Waclawiw, Myron, Alston-Smith, Beverly, Cooper-Arnold, Katharine, Klingman, Karin L., Desvigne-Nickens, Patrice, Hoffmann, Udo, Ribaudo, Heather J., Douglas, Pamela S.

“…Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and…”
Get full text

Airway inflammation and etiology of acute exacerbations of chronic bronchitis by Sethi, S, Muscarella, K, Evans, N, Klingman, K L, Grant, B J, Murphy, T F

“…The etiologic role of bacterial pathogens isolated from sputum culture in 40 to 50% of acute exacerbations of chronic bronchitis (AECB) is controversial. If…”
Get more information

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention by Fowler, Mary G, Qin, Min, Fiscus, Susan A, Currier, Judith S, Flynn, Patricia M, Chipato, Tsungai, McIntyre, James, Gnanashanmugam, Devasena, Siberry, George K, Coletti, Anne S, Taha, Taha E, Klingman, Karin L, Martinson, Francis E, Owor, Maxensia, Violari, Avy, Moodley, Dhayendre, Theron, Gerhard B, Bhosale, Ramesh, Bobat, Raziya, Chi, Benjamin H, Strehlau, Renate, Mlay, Pendo, Loftis, Amy J, Browning, Renee, Fenton, Terence, Purdue, Lynette, Basar, Michael, Shapiro, David E, Mofenson, Lynne M

“…In this randomized, controlled trial in Africa and India, combination antiretroviral therapy was more effective than standard therapy in preventing…”
Get full text

Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s by Kuritzkes, Daniel R., Ribaudo, Heather J., Squires, Kathleen E., Koletar, Susan L., Santana, Jorge, Riddler, Sharon A., Reichman, Richard, Shikuma, Cecilia, Meyer, William A., Klingman, Karin L., Gulick, Roy M.

“…Objective. We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based…”
Get full text

The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV by Lake, Jordan E, Kitch, Douglas W, Kantor, Amy, Muthupillai, Raja, Klingman, Karin L, Vernon, Christina, Belaunzaran-Zamudio, Pablo F, Fichtenbaum, Carl J, Heath, Sonya, Perazzo, Hugo, Corey, Kathleen, Brown, Todd T, Landay, Alan, Sattler, Fred, Erlandson, Kristine M

Get full text

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers by Hoffmann, Udo, Lu, Michael T., Olalere, Devvora, Adami, Elizabeth C., Osborne, Michael T., Ivanov, Alex, Aluru, John Sukumar, Lee, Saeyun, Arifovic, Nadja, Overton, Edgar Turner, Fichtenbaum, Carl J., Aberg, Judith A., Alston-Smith, Beverly, Klingman, Karin L., Waclawiw, Myron, Burdo, Tricia H., Williams, Kenneth C., Zanni, Markella V., Desvigne-Nickens, Patrice, Cooper-Arnold, Katharine, Fitch, Kathleen V., Ribaudo, Heather, Douglas, Pamela S., Grinspoon, Steven K.

“…People with HIV (PWH) have increased cardiovascular events, inflammation, and high-risk coronary atherosclerosis. Statin therapy has been shown to lower the…”
Get full text

Screening and Enrollment by Sex in Human Immunodeficiency Virus Clinical Trials in the United States by Smeaton, Laura M, Kacanek, Deborah, Mykhalchenko, Kateryna, Coughlin, Kristine, Klingman, Karin L, Koletar, Susan L, Barr, Elizabeth, Collier, Ann C

“…Abstract Background Women are underrepresented in human immunodeficiency virus (HIV) research in the United States. To determine if women screening for HIV…”
Get full text

Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens by Bhattacharya, Debika, Gupta, Amita, Tierney, Camlin, Huang, Sharon, Peters, Marion G, Chipato, Tsungai, Martinson, Frances, Mohtashemi, Neaka, Dula, Dingase, George, Kathy, Chaktoura, Nahida, Klingman, Karin L, Gnanashanmugam, Devasena, Currier, Judith S, Fowler, Mary G

“…Severe hepatotoxicity in people with human immunodeficiency virus (HIV) receiving efavirenz (EFV) has been reported. We assessed the incidence and risk factors…”
Get full text

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial by Arenas-Pinto, Alejandro, Grund, Birgit, Sharma, Shweta, Martinez, Esteban, Cummins, Nathan, Fox, Julie, Klingman, Karin L, Sedlacek, Dalibor, Collins, Simon, Flynn, Patricia M, Chasanov, William M, Kedem, Eynat, Katlama, Christine, Sierra-Madero, Juan, Afonso, Claudia, Brouwers, Pim, Cooper, David A

“…Abstract Background Randomized trials have shown increased risk of suicidality associated with efavirenz (EFV). The START (Strategic Timing of Antiretroviral…”
Get full text

Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men by Le, Catherine N, Britto, Paula, Brummel, Sean S, Hoffman, Risa M, Li, Jonathan Z, Flynn, Patricia M, Taha, Taha E, Coletti, Anne, Fowler, Mary Glenn, Bosch, Ronald J, Gandhi, Rajesh T, Klingman, Karin L, McIntyre, James A, Currier, Judith S

“…OBJECTIVE(S):The short-term safety of treatment interruptions, a necessary part of cure studies, is not well established, particularly in women. We explored…”
Get full text

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305) by Gulick, Roy M., Wilkin, Timothy J., Chen, Ying Q., Landovitz, Raphael J., Amico, K. Rivet, Young, Alicia M., Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., McGowan, Ian, Cottle, Leslie M., Andrade, Adriana, Marcus, Cheryl, Klingman, Karin L., Chege, Wairimu, Rinehart, Alex R., Rooney, James F., Andrew, Philip, Salata, Robert A., Magnus, Manya, Farley, Jason E., Liu, Albert, Frank, Ian, Ho, Ken, Santana, Jorge, Stekler, Joanne D., McCauley, Marybeth, Mayer, Kenneth H.

“…Background. Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis. Methods. Phase 2 48-week safety/tolerability study…”
Get full text

Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy by Kalayjian, Robert C, Albert, Jeffrey M, Cremers, Serge, Gupta, Samir K, McComsey, Grace A, Klingman, Karin L, Fichtenbaum, Carl J, Brown, Todd T, Taiwo, Babafemi O

“…OBJECTIVE:We compared bone mineral density (BMD) changes and their correlates, between men and women participating in two randomized trials of initial…”
Get full text

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial by Gulick, Roy M, Wilkin, Timothy J, Chen, Ying Q, Landovitz, Raphael J, Amico, K Rivet, Young, Alicia M, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, McGowan, Ian, Cottle, Leslie M, Andrade, Adriana, Marcus, Cheryl, Klingman, Karin L, Chege, Wairimu, Rinehart, Alex R, Rooney, James F, Andrew, Philip, Salata, Robert A, Siegel, Marc, Manabe, Yukari C, Frank, Ian, Ho, Ken, Santana, Jorge, Stekler, Joanne D, Swaminathan, Shobha, McCauley, Marybeth, Hodder, Sally, Mayer, Kenneth H

“…Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP). To assess the safety and tolerability of MVC-containing PrEP over 48 weeks in U.S…”
Get full text

Low Rate of Sex-specific Analyses in Presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) Meeting, 2018: Room to Improve by Gandhi, Monica, Smeaton, Laura M, Vernon, Christina, Scully, Eileen P, Gianella, Sara, Poongulali, Selvamuthu, Sheth, Anandi N, Van Schalkwyk, Marije, Klingman, Karin L, Short, William R, Opollo, Valarie S, Cohn, Susan E, Scarsi, Kimberly K, Firnhaber, Cindy, Bares, Sara, Swaminathan, Shobha, Mngqibisa, Rosie, Connick, Elizabeth

Get full text

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum by Smeaton, Laura M, Kileel, Emma M, Grinsztejn, Beatriz, Gardner, Edward M, Starr, Kate, Murry, Melissa L, Desvigne-Nickens, Patrice, Alston-Smith, Beverly, Waclawiw, Myron A, Cooper-Arnold, Katharine, Madruga, José V, Sangle, Shashi, Fitch, Kathleen V, Zanni, Markella V, Douglas, Pamela S, Ribaudo, Heather J, Grinspoon, Steven K, Klingman, Karin L

“…Abstract Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported…”
Get full text